Imbruvica (ibrutinib)is a once-daily oral medication (capsule or tablet) that has shown long-term effectiveness (five years+) for patients who have already been treated for CLL.3Ibrutinib has subsequently been approved for front-line use in newly-diagnosed CLL patients as well. Ibrutinib works ...
New treatment developments CAR-T cells as a safer alternative to transplantation Main side effect is cytokine release syndrome CAR-T cells induce remissions in >80% of patients with ALL but only 25% of patients with CLL CLL patients who respond have a healthier immune system One patient went i...
The version of you an abusive adult child or intimate partner needs, wants and tries to get out of you is a scared, overwhelmed, unstable, anxious ridden human who will put up with being treated poorly. No one, not a husband, parent, adult child, sibling or friend or greater society ...
How is diffuse large B-cell lymphoma treated?Diffuse Large B-Cell Lymphoma:Diffuse large B-cell lymphoma (DLBCL) is a type of non-Hodkin's lymphoma, which is a cancer that affects white blood cells in the body (B-cells are a type of white blood cell). The true cause of DLBCL is ...
What is B-cell lymphoblastic leukemia? How pancreatic cancer is treated? How can pancreatic cancer be treated? Is CLL a non-Hodgkin lymphoma? What is the survival rate of Hodgkin lymphoma? How aggressive is non-Hodgkin lymphoma? How is sinus cancer treated? How is multiple myeloma treated? Ho...
Advances in the use of prognostic factors that identify patients at high risk for progression have led us to the question whether there is still a role for a “watch and wait” approach in asymptomatic high-risk patients or whether they should be treated earlier in their disease course. ...
If natural disasters become so frequent that a single health plan could be affected by multiple distinct disasters within the performance measurement period, which is typically a year, this could make plans more susceptible to seeing meaningfully negative disaster effects. So, disaster effects that wer...
Dr Raghav on the Safety Profile of ABBV-400 Plus Chemo and Bevacizumab in Previously Treated mCRC Dr Lee on the Rationale for Using Integrative Medicine in Patients With GI Cancers Dr Vlachou on Primary Tumor Responses With Enfortumab Vedotin in Upper Tract Urothelial Cancer ...
BCL-2 is an anti-apoptotic protein implicated in the pathobiology of many iNHLs, most known in the context of the BCL2:IGH (t14;18) translocation in FL. Venetoclax, an oral BCL2 inhibitor, has considerable activity in CLL and MCL, but surprisingly disappointing activity in FL (ORR 38%,...
For many doctors and researchers, immunotherapy that uses someone's own immune system to target and attack cancer cells is the next and best frontier of cancer treatment. Chimeric antigen receptor T-cell therapy, or CAR-T cell therapy, is one type of imm